Lewy Body Dementia Treatment Market Size (7MM) was USD 670 Million in 2022 and is projected to grow by 2034. Companies are developing therapies for treatment

Lewy Body Dementia Treatment Market Size, Drugs, Companies

Lewy Body Dementia Market Infographics

1 Key Insights
2 Report Introduction
3 DLB Market Overview at a Glance
3.1 Market Share (%) Distribution of DLB by Therapies in 2020
3.2 Market Share (%) Distribution of DLB by Therapies in 2034
4 Epidemiology and Market Forecast Methodology
5 Executive Summary of DLB
6 Key Events
7 DLB: Disease Background and Overview
7.1 Introduction
7.2 Classification of LBD
7.3 Etiology and Risk factors
7.4 Clinical Manifestations
7.5 Pathophysiology
7.5.1 Molecular mechanisms of Lewy body disorders
7.6 Diagnosis
7.6.1 Diagnostic Criteria for DLB
7.6.1.1 Diagnosis and management of DLB: Fourth consensus report of the DLB consortium
7.6.1.2 Diagnostic Criteria for Major Neurocognitive Disorder with Lewy Bodies (DSM-5)
7.7 Management and Treatment
7.7.1 Treatment Guidelines
7.7.1.1 Management Guideline for Lewy body dementia (2020)
7.7.1.1.1 Basic principles of LBD management
7.7.1.1.2 Managing cognitive symptoms
7.7.1.1.3 Managing neuropsychiatric symptoms
7.7.1.1.4 Managing Parkinsonian symptoms
7.7.1.1.5 Managing autonomic dysfunction
7.7.1.2 Managing sleep disturbances
7.7.1.3 Dementia Disease Clinical Practice Guideline 2017: The Japanese Society of Neurology
7.7.1.4 Clinical Practice with Anti-dementia drugs: a Consensus Statement from British Association for Psychopharmacology
7.7.1.5 Dementia: Assessment, Management and Support for People Living With Dementia and Their Carers: NICE Guideline 2018
8 Epidemiology and Patient Population of DLB
8.1 Key Findings
8.2 Assumptions and Rationale: The 7MM
8.2.1 The United States
8.2.2 EU4 and the United Kingdom
8.2.2.1 Germany
8.2.2.2 France
8.2.2.3 Italy
8.2.2.4 Spain
8.2.2.5 The UK
8.2.3 Japan
8.3 Total Prevalent cases of Dementia in the 7MM
8.4 Total Diagnosed Prevalent cases of Dementia in the 7MM
8.5 Total Diagnosed Prevalent cases of DLB in the 7MM
8.6 The United States
8.6.1 Prevalent cases of Dementia in the US
8.6.2 Diagnosed Prevalent cases of Dementia in the US
8.6.3 Diagnosed Prevalent cases of DLB in the US
8.6.4 Gender-specific Diagnosed Prevalent cases of DLB in the US
8.6.5 Age-specific Diagnosed Prevalent cases of DLB in the US
8.7 EU4 and the UK
8.7.1 Germany
8.7.1.1&nbsp;&nbsp; Prevalent cases of Dementia in Germany
8.7.1.2&nbsp;&nbsp; Diagnosed Prevalent cases of Dementia in Germany
8.7.1.3&nbsp;&nbsp; Diagnosed Prevalent cases of DLB in Germany
8.7.1.4&nbsp;&nbsp; Gender-specific Diagnosed Prevalent cases of DLB in Germany
8.7.1.5&nbsp;&nbsp; Age-specific Diagnosed Prevalent cases of DLB in Germany
8.7.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France
8.7.2.1 Prevalent cases of Dementia in France
8.7.2.2 Diagnosed Prevalent cases of Dementia in France
8.7.2.3 Diagnosed Prevalent cases of DLB in France
8.7.2.4 Gender-specific Diagnosed Prevalent cases of DLB in France
8.7.2.5 Age-specific Diagnosed Prevalent cases of DLB in France
8.7.3 Italy
8.7.3.1 Prevalent cases of Dementia in Italy
8.7.3.2 Diagnosed Prevalent cases of Dementia in Italy
8.7.3.3 Diagnosed Prevalent cases of DLB in Italy
8.7.3.4 Gender-specific Diagnosed Prevalent cases of DLB in Italy
8.7.3.5 Age-specific Diagnosed Prevalent cases of DLB in Italy
8.7.4 Spain
8.7.4.1 Prevalent cases of Dementia in Spain
8.7.4.2 Diagnosed Prevalent cases of Dementia in Spain
8.7.4.3 Diagnosed Prevalent cases of DLB in Spain
8.7.4.4 Gender-specific Diagnosed Prevalent cases of DLB in Spain
8.7.4.5 Age-specific Diagnosed Prevalent cases of DLB in Spain
8.7.5 The UK
8.7.5.1 Prevalent cases of Dementia in the UK
8.7.5.2 Diagnosed Prevalent cases of Dementia in the UK
8.7.5.3 Diagnosed Prevalent cases of DLB in the UK
8.7.5.4 Gender-specific Diagnosed Prevalent cases of DLB in the UK
8.7.5.5 Age-specific Diagnosed Prevalent cases of DLB in the UK
8.8 Japan
8.8.1 Prevalent cases of Dementia in Japan
8.8.2 Diagnosed prevalent cases of Dementia in Japan
8.8.3 Diagnosed prevalent cases of DLB in Japan
8.8.4 Gender-specific Diagnosed Prevalent cases of DLB in Japan
8.8.5 Age-specific Diagnosed Prevalent cases of DLB in Japan
9 Patient Journey
10 Emerging Drugs
10.1 Key Cross Competition
10.2 Neflamapimod: EIP Pharma Inc.
10.2.1 Product description
10.2.2 Other development activities
10.2.3 Clinical development
10.2.4 Clinical trial information
10.2.5 Safety and efficacy
10.2.6 Product profile
10.2.7 Analysts&rsquo; views
10.3 CT1812: Cognition Therapeutics
10.3.1 Product description
10.3.2 Other development activities
10.3.3 Clinical development
10.3.4 Clinical trial information
10.3.5 Product profile
10.3.6 Analysts&rsquo; views
List will be continued in the report&hellip;
11 DLB: Seven Major Market Analysis
11.1 Key Findings
11.2 Market Outlook
11.3 Conjoint Analysis
11.4 Key Market Forecast Assumptions
11.5 Market Size of DLB in the 7MM
11.6 Market Size of DLB by Therapies in the 7MM
11.7 Market Size of DLB in the United States
11.7.1 Total Market Size of DLB
11.7.2 Market Size of DLB by Therapies
11.8 Market Size of DLB in EU4 and the UK
11.8.1 Germany
11.8.1.1 Total Market Size of DLB
11.8.1.2 Market Size of DLB by Therapies
11.8.2 France
11.8.2.1 Total Market Size of DLB
11.8.2.2 Market Size of DLB by Therapies
11.8.3 Italy
11.8.3.1 Total Market Size of DLB
11.8.3.2 Market Size of DLB by Therapies
11.8.4 Spain
11.8.4.1 Total Market Size of DLB
11.8.4.2 Market Size of DLB by Therapies
11.8.5 The UK
11.8.5.1 Total Market Size of DLB
11.8.5.2 Market Size of DLB by Therapies
11.9 Market Size of DLB in Japan
11.9.1 Total Market Size of DLB
11.9.2 Market Size of DLB by Therapies
12 Key Opinion Leaders&rsquo; View
13 SWOT Analysis
14 Unmet Needs
15 Market Access and Reimbursement
15.1 The United States
15.1.1 Centre for Medicare and Medicaid Services (CMS)
15.2 EU4 and the UK
15.2.1 Germany
15.2.2 France
15.2.3 Italy
15.2.4 Spain
15.2.5 The United Kingdom
15.3 Japan
15.3.1 MHLW
16 Appendix
16.1 Bibliography
16.2 Acronyms and Abbreviations
16.3 Report Methodology
17 DelveInsight Capabilities
18 Disclaimer
19 About DelveInsight

DelveInsight's “Dementia with Lewy Bodies (DLB) – Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the DLB, historical and forecasted epidemiology as well as the DLB market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Lewy Body Dementia Market

Lewy Body Dementia Market Insights, Epidemiology and Market Forecast – 2034

DelveInsight's Lewy Body Dementia Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Lewy Body Dementia, 